@article{oai:repo.qst.go.jp:00048567,
 author = {Nakajima, Kenichi and J.H.A.Scholte, Arthur and Nakata, Tomoaki and C., Dimitriu-Leen  Aukelien and Chikamori, Taishiro and Yoshinaga, Keiichiro and V., Vitola João and 吉永 恵一郎},
 issue = {3},
 journal = {Jouranl of nuclear cardiology: official publication of the American Society of Nuclear Cardiology},
 month = {Mar},
 note = {Cardiac sympathetic nervous system dysfunction is closely associated with risk of serious cardiac events in patients with heart failure (HF), including HF progression, pump-failure death, and sudden cardiac death by lethal ventricular arrhythmia. For cardiac sympathetic nervous system imaging, 123I-meta-iodobenzylguanidine (123I-MIBG) was approved by the Japanese Ministry of Health, Labour and Welfare in 1992 and has therefore been widely used since in clinical settings. 123I-MIBG was also later approved by the Food and Drug Administration (FDA) in the United States of America (USA) and it was expected to achieve broad acceptance. In Europe, 123I-MIBG is currently used only for clinical research. This review article is based on a joint symposium of the Japanese Society of Nuclear Cardiology (JSNC) and the American Society of Nuclear Cardiology (ASNC), which was held in the annual meeting of JSNC in July 2016. JSNC members and a member of ASNC discussed the standardization of 123I-MIBG parameters, and clinical aspects of 123I-MIBG with a view to further promoting 123I-MIBG imaging in Asia, the USA, Europe, and the rest of the world.},
 pages = {952--960},
 title = {Cardiac sympathetic nervous system imaging with 123I-meta-iodobenzylguanidine: Perspectives from Japan and Europe},
 volume = {24},
 year = {2017}
}